Stock Research for RGLS

RGLS

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

RGLS Stock Chart & Research Data

The RGLS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the RGLS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


RGLS Due diligence Resources & Stock Charts

The RGLS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View RGLS Detailed Price Forecast - CNN Money CNN View RGLS Detailed Summary - Google Finance
Yahoo View RGLS Detailed Summary - Yahoo! Finance Zacks View RGLS Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View RGLS Trends & Analysis - Trade-Ideas Barrons View RGLS Major Holders - Barrons
NASDAQ View RGLS Call Transcripts - NASDAQ Seeking View RGLS Breaking News & Analysis - Seeking Alpha
Spotlight View RGLS Annual Report - CompanySpotlight.com OTC Report View RGLS OTC Short Report - OTCShortReport.com
TradeKing View RGLS Fundamentals - TradeKing Charts View RGLS SEC Filings - Bar Chart
WSJ View Historical Prices for RGLS - The WSJ Morningstar View Performance/Total Return for RGLS - Morningstar
MarketWatch View the Analyst Estimates for RGLS - MarketWatch CNBC View the Earnings History for RGLS - CNBC
StockMarketWatch View the RGLS Earnings - StockMarketWatch MacroAxis View RGLS Buy or Sell Recommendations - MacroAxis
Bullish View the RGLS Bullish Patterns - American Bulls Short Pains View RGLS Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View RGLS Stock Mentions - StockTwits PennyStocks View RGLS Stock Mentions - PennyStockTweets
Twitter View RGLS Stock Mentions - Twitter Invest Hub View RGLS Investment Forum News - Investor Hub
Yahoo View RGLS Stock Mentions - Yahoo! Message Board Seeking Alpha View RGLS Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for RGLS - SECform4.com Insider Cow View Insider Transactions for RGLS - Insider Cow
CNBC View RGLS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for RGLS - OTC Markets
Yahoo View Insider Transactions for RGLS - Yahoo! Finance NASDAQ View Institutional Holdings for RGLS - NASDAQ


Stock Charts

FinViz View RGLS Stock Insight & Charts - FinViz.com StockCharts View RGLS Investment Charts - StockCharts.com
BarChart View RGLS Stock Overview & Charts - BarChart Trading View View RGLS User Generated Charts - Trading View




Latest Financial News for RGLS


Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
Posted on Monday January 07, 2019

Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.


Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
Posted on Friday January 04, 2019

LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study.  The Company terminated that mouse study prematurely at week 14.  The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.


Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
Posted on Thursday December 20, 2018

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...


Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Wednesday November 28, 2018

NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.